Skip to main content
Download PDF

Patients with longstanding psoriatic arthritis can achieve DAPSA remission or low disease activity and it correlates to better functional outcomes: results from a Latin-American real-life cohort

Advances in Rheumatology volume 64, Article number: 3 (2024) Cite this article

Abstract

Background

Patients with psoriatic arthritis (PsA) experience reduced physical function and impaired quality of life. Better patient-reported functional outcomes are found when lower disease activity is achieved.

Objectives

To evaluate the variation of physical function by HAQ-DI over time in PsA patients treated with standard therapy in a real-life setting: to verify predictors of achieving a minimum clinically important difference (MCID) in function by HAQ-DI (ΔHAQ-DI ≤ − 0.35) and to measure the impact of achieving REM/LDA on long-term function by HAQ-DI.

Methods

This is a longitudinal analysis of a real-life retrospective cohort. Data from PsA patients with at least 4 years of follow-up in the PsA clinic from 2011 to 2019 were extracted from electronic medical records. The variations of physical function by HAQ-DI and disease activity by DAPSA over time were calculated. A multivariate hierarchical regression model was applied to verify predictors of MCID in HAQ-DI. A comparison of HAQ-DI variation between patients with DAPSA REM, LDA, moderate and high disease activity was made using the generalized estimating equation model (GEE), adjusted by Bonferroni test. The Spearman correlation method was applied to verify the correlation of ΔDAPSA and ΔHAQ-DI over time. Statistical analysis was performed in SPSS program version 21.0.

Results

Seventy-three patients were included in the analysis. Physical function measured by HAQ-DI was determined by PsA disease activity measured by DAPSA (p < 0.000). A moderate and statistically significant correlation between ΔDAPSA and ΔHAQ-DI was observed (rs = 0.60; p < 0.001). Only patients in DAPSA REM demonstrated a constant decline in HAQ-DI scores during the follow-up. White ethnicity and older age at baseline were predictors for not achieving MCID in HAQ-DI [RR 0.33 (0.16–0.6795% CI p = 0.002) and RR 0.96 (0.93–0.9895% CI p < 0.000), respectively, while higher scores of HAQ-DI at baseline were predictors of achieving MCID [RR 1.71 (1.12–2.6095%CI p = 0.013)].

Conclusions

In PsA, patients who maintained DAPSA REM/LDA over time had better long-term functional outcomes. Higher HAQ-DI scores at baseline, non-white ethnicity and younger age were predictors for achieving a clinical meaningful improvement of HAQ-DI.

Background

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy associated with psoriasis, with an estimated prevalence of 133 every 100,000 subjects worldwide [1]. Poor disease control can lead to severe functional impairment and reduced health-related quality of life, with a significant global health burden [2]. Besides that, lower disease activity leads to better patient-reported functional outcomes [3,4,5].Therefore, it is widely recommended that the treatment goals for PsA should be remission or, alternatively, low to minimal disease activity, although there is no consensus on the best tool to assess or define remission [6,7,8]. In that sense, measurement of function and its correlation to disease activity in PsA constitute a major concern in Rheumatology.

To quantify disease activity in PsA, Disease Activity Index for PsA (DAPSA) and Minimal Disease Activity criteria (MDA) are the main tools currently used by Rheumatologists in daily practice [9, 10]. As for the assessment of physical function, patient-reported Health Assessment Questionnaire-Disability Index (HAQ-DI) is proven to be a valuable measure in PsA. Despite originally being developed for use in patients with rheumatoid arthritis [11,12,13], HAQ-DI has been validated and widely used in PsA clinical trials, even showing correlation to the effectiveness of active therapies when compared to placebo [14].

Clinical data correlating disease activity and function were mainly obtained in randomized clinical trials (RCTs), in which patients are followed in a controlled environment, have less comorbidities, a moderate to high disease activity at baseline and are usually treated with immunobiological disease-modifying antirheumatic drugs (bDMARDs) [3–5, 15, 16]. In such context, a major improvement in HAQ-DI scores over time is expected. However, those results might not be applicable in low and middle income countries, where patients have poor access to bDMARDs and commonly have long-term PsA, chronic deformities and lower rates of adherence to therapy.

The primary objective of this study was to evaluate the variation of physical function by HAQ-DI over time in PsA patients treated with standard therapy in a real-life setting. Secondary objectives were to quantify patients achieving a minimum clinically important difference (MCID) in function by HAQ-DI (ΔHAQ-DI ≤ − 0.35) [17]; to verify predictors of achieving a MCID in HAQ-DI; to quantify patients achieving sustained DAPSA remission (REM) or low disease activity (LDA) and patients achieving sustained MDA; and to measure the impact of achieving DAPSA REM or LDA (REM/LDA) on long-term function.

Methods

Study design

This is a longitudinal analysis of a real-life retrospective cohort of patients followed in Hospital de Clínicas de Porto Alegre’s PsA clinic from 2011 to 2019. Inclusion criteria were ≥ 18-year-old patients fulfilling the Classification Criteria for Psoriatic Arthritis (CASPAR) [18] with at least 4 years of follow-up in electronic medical records and at least two visits with HAQ-DI registered measurements within a 12-month interval. Data previously collected and registered in routine patient care from January 2011 to March 2019 were extracted from electronic medical records between August and October 2019. All data have been anonymized before analysis.

Data collection

Demographics and clinical data collected at baseline were: patient age (years), gender, ethnicity (white or non-white), year of PsA diagnosis and year of PsA symptoms onset. Clinical data collected at baseline and at each subsequent visit were: patient global visual analogue scale (VAS) (0–10 cm); patient pain VAS (0–10 cm); patient fatigue VAS (0–10 cm); physician and patient skin VAS (0–10 cm); tender entheseal points with the Maastrich Ankylosing Spondylitis Enthesitis Score (MASES) (0–13); tender joint count (TJC) (0–68), swollen joint count (SJC) (0–66); serum C-reactive protein (CPR) level in mg/dL; assessment of disease activity by DAPSA LDA and LDA + REM and MDA; assessment of physical function by HAQ-DI score (0–3).

Disease activity by DAPSA was calculated by the sum of TJC (0–68), SJC (0–66), patient global VAS (0–10), patient pain VAS (0–10) and serum CRP (mg/dL). Remission (REM) was defined by DAPSA 0–4 and low disease activity (LDA)was defined by DAPSA 5–14 [9]. It was also recorded, at each consultation, if the patient achieved the state of Minimal Disease Activity (MDA), fulfilling 5 or more of the 7 following criteria: TJC ≤ 1, SJC ≤ 1, psoriasis body surface area (BSA) ≤ 3%, patient pain VAS ≤ 1.5, patient global VAS ≤ 2, tender entheseal points ≤ 1 and HAQ-DI ≤ 0,5 [10]. When the longitudinal analysis was performed, sustained REM/LDA by DAPSA and sustained MDA were defined as maintenance of REM/LDA or MDA over a period of >  = 12 months during follow-up.

Treatment data were also retrieved in each patient visit, including the use of synthetical disease-modifying anti-rheumatic drugs (sDMARDs): methotrexate, sulfassalazine, leflunomide;and the bDMARDs available at the time of study conduction: adalimumab, etanercept, infliximab, golimumab, ustekinumab and secukinumab. Patients were receiving standard care for PsA according to current national and international guidelines and recommendations [6,7,8].

Statistical analysis

Sample size calculation was performed using WinPEP version 11.43 and was based on studies of Mease P. et al. (2018) [2] and Strand V. et al. (2018) [15]. Considering a 5% significance level, 90% power, an expected variation of 0.3 points on HAQ-DI in 4 years and an estimated standard deviation (SD) of 0.5 points, a minimal sample size of 43 patients was required. Quantitative variables were analyzed as mean and SD if normally distributed or median and interquartile range (25–75%) if they presented a non-normal distribution. Categorical variables were described as absolute numbers (n) and relative frequencies (percentage or %).

To evaluate the variation of physical function by HAQ-DI over time, we calculated the difference between median HAQ-DI at baseline and median HAQ-DI at the final patient visit (ΔHAQ-DI). To quantify patients achieving a MCID in HAQ-DI, we calculated the relative frequency (%) of patients with a ΔHAQ-DI ≤ − 0.35.

To verify which variables were predictors of achieving MCID in HAQ-DI, a multivariate hierarchical regression model was applied. Firstly, patients were divided in two groups according to achieving or not a MCID in HAQ-DI and the univariate analysis was performed. Then, variables with a p value of < 0.20 in this regression were selected for a second multivariate analysis, for which the significance level adopted was 5% (p < 0.05).

To quantify patients achieving DAPSA REM/LDA and MDA over time, we calculated the relative frequencies (%) of sustained REM/LDA and sustained MDA. To measure the impact of achieving DAPSA REM/LDA on long-term function by HAQ-DI, we performed a longitudinal analysis of median DAPSA and median HAQ-DI at baseline and at years 1, 2, 3, 4, 5 and 6, and performed a comparison of HAQ-DI variation between patients with DAPSA REM (= < 4), LDA (4–14), moderate (14–28) and high disease activity (> 28), using the generalized estimating equation model (GEE), adjusted by Bonferroni test. Also, the variation of median DAPSA at baseline and at the final patient visit was calculated (ΔDAPSA) and the Spearman correlation method was applied to verify the correlation of ΔDAPSA and ΔHAQ-DI over time.

Statistical analysis was performed in SPSS program version 21.0.

Ethical considerations

The study followed international clinical research standards and was approved by the local ethics committee. Researchers signed a confidentiality term for the use of electronic data. The written informed consent from patients was not required because it was a retrospective study with data from routine care. Novartis collaborated with the study, but did not participate in the data collection, analysis or description of the results.

Results

Seventy-three patients were included in the analysis, of which 58.9% (n = 43) were women and 89% (n = 65) had white ethnicity. At baseline, the mean (SD) age was 54.3 (9.9) years old, the median time (25–75th) of diagnosis of PsA was 8 (3–15) years and there was a median (25–75th) of 12 (5–20) years since the onset of articular symptoms until the baseline visit. Mean (SD) follow-up time was 6.2 (1.2) years. Mean (SD) number of patient visits with HAQ-DI registered measurements was 11.58 (4.02), corresponding to a mean of 1.86 visits per year. Further baseline and longitudinal data are described in Table 1.

Table 1 Characteristics of the 73 patients with PsA included in the analysis and univariate analysis of predictive factors to achieving a clinically meaningful improvement in HAQ-DI, as defined by MCID > 0.35
Full size table

When analyzing the total sample over 6 years of follow-up, there was no statistically significant improvement of physical function [baseline median (25-75th) HAQ-DI 1.625 (1.0625–2.050), final median HAQ-DI 1.50 (0.75–2.0625), ΔHAQ-DI: − 0.125 (− 0.5 to + 0.375), p = 0. 214]. Although there was no statistically significant improvement of physical function when the total sample was analyzed, when patients were analyzed individually, 37% of patients (n = 27) showed a clinically meaningful improvement in HAQ-DI (Table 1) despite having long-term PsA.

In the univariate analysis, the variables associated to a MCID in HAQ-DI with a p-value of < 0.20were:age, ethnicity, patient global VAS assessment, median HAQ-DI at baseline, MASES at baseline, sustained MDA, achievement of DAPSA REM/LDA in at least one visit during the follow-up and use of sDMARDs for at least twelve months (Table 1, in bold).

In the multivariate analysis, older age at baseline and white ethnicity were predictors for the non-achievement of the MCID in HAQ-DI [RR 0.96 (95% CI 0.93–0.98, p < 0.001) and RR 0.33 (95% CI 0.16–0.67, p = 0.002), respectively, while a higher score in HAQ-DI at baseline and the use of sDMARD for more than 12 months were predictors of achievement of the MCID in HAQ-DI [RR 1.71 (95% CI 1.12–2.60, p = 0.013) and RR 3.86 (95% CI 1.21–12.3, p = 0.022), respectively] (Table 2, in bold).

Table 2 Multivariate analysis of predictive factors for patients achieving MCID in HAQ-DI (ΔHAQ-DI ≤ − 0.35)
Full size table

The assessment of disease activity over time showed that 56.2% of patients achieved sustained DAPSA REM/LDA and 20.5% achieved sustained MDA in the total sample. The year-by-year longitudinal analysis of function and disease activity is shown in Table 3.

Table 3 Information on disease activity, physical function and use of bDMARDs during 6 years of follow-up
Full size table

A histogram was constructed to display the median HAQ-DI at each year of follow-up according to the four categories of DAPSA (REM, LDA, moderate and high disease activity) (Fig. 1). As expected, the physical function measured by HAQ-DI was determined by the disease activity measured by DAPSA (interaction test p < 0.0001). There was an improvement of function in the first three years of follow-up, which was observed in patients in REM, LDA and moderate disease activity by DAPSA, but not in patients with high disease activity. This period of better function was coincidental to the period at which most patients were receiving bDMARDs (Table 3). The only group that showed a sustained reduction in HAQ-DI during the six years was that of patients in DAPSA remission (Fig. 1).

Fig. 1
figure 1

The median HAQ-DI at each year of follow-up divided into four categories according to DAPSA. HAQ-DI Health Assessment Questionnaire-Disability Index, DAPSA Disease Activity Index for PsA REM: remission, LDA Low disease activity, MDA Moderate disease activity, HDA High disease activity. Patients in remission had the lowest scores on HAQ-DI

Full size image

The median (25–75th) DAPSA decreased during follow-up [baseline DAPSA 16.3 (11.4–22.3), final DAPSA 12.5 (5.9–18.6),ΔDAPSA − 3.9 (− 10.1/ + 2.5), p = 0.019].A moderate and statistically significant correlation was observed between ΔDAPSA and ΔHAQDI (rs = 0.60; p < 0.001) (Fig. 2), demonstrating that a reduction in disease activity was associated with an improvement in physical function.

Fig. 2
figure 2

Comparison of the variation of disease activity (ΔDAPSA) and physical function ΔHAQ-DI. HAQ-DI Health Assessment Questionnaire-Disability Index, DAPSA Disease Activity Index for PsA

Full size image

Discussion

This study was conducted in a real-life setting and led to several interesting results. Firstly, it demonstrated that even patients with long-term PsA can achieve therapeutic targets and obtain an improvement in function; in this cohort, 56.2% of patients achieved sustained DAPSA REM/LDA, 20.5% achieved sustained MDA and 37% obtained a minimum clinically significant improvement in function by HAQ-DI. Secondly, it demonstrated that demographic variables such as younger age and non-white ethnicity, as well as worse functional scores at baseline were predictors of patients achieving a clinically significant improvement in function during follow-up. Finally, we observed that physical function over time was determined by disease activity measured by DAPSA and only the group of patients in DAPSA remission showed values of HAQ-DI constantly lower than 0.5 points, comparable to healthy subjects.

As expected, this improvement was lower in comparison to the clinical trials of patients taking bDMARDs [19, 20], since our cohort includes patients with delayed and difficult access to therapy.

There was a significant improvement in function by HAQ-DI at the first three years of follow-up (Table 2, Fig. 1). However, this tendency was not sustained over the following years, which might be explained by intersubject variability. To our knowledge, other studies evaluating HAQ-DI in PsA present shorter follow-up times (3 to 12 months), which imposes difficulties in comparison to other results [21,22,23].

Regarding the predictors of MCID, our results were similar to those of previous studies. Other cohorts for assessing physical function measured by HAQ-DI over time in patients with PsA pointed age as an important factor correlated with worse HAQ-DI scores and lower improvement over time [20, 24, 25], showing the influence of comorbidities and established deformities in function. Patients with higher HAQ-DI scores at baseline also had a greater decrease over the follow up, which could be explained by regression towards the mean. The use of sDMARD for more than 12 months was a predictive factor for obtaining MCID, demonstrating the importance of regular treatment in controlling disease activity and improving quality of life.

This cohort showed that white ethnicity was a predictor of not obtaining MCID. Literature describes a higher prevalence of PsA in North America and Northern Europe [26], which is associated with genetic and environmental factors, such as obesity, alcoholism, and the presence of psoriasis. However, ethnicity has not been described as a predictor of improvement in function. Other studies demonstrate that African-Americans with PsA have greater impaired quality of life [27], reinforcing that patients with higher initial HAQ-DI are more likely to achieve MCID.

Several randomized clinical trials comparing biological therapy and placebo have demonstrated MCID in the group using bDMARDs [21, 22, 28]. This direct association was not found in our study. A plausible explanation may be the longer follow-up time and the influence of poor adherence in real life. However, patients taking bDMARDs in our cohort had lower disease activity.

The sample size may have been a limiting factor to find more significant differences between the categories of DAPSA, because the number of patients in each group would not be enough to compare the median HAQ-DI between them. However, it was enough to correlate the variation of DAPSA and HAQ-DI over time, as well as to identify some predictive factors for MCID. The subjectivity of the instruments used must be considered. The DAPSA, MDA and HAQ-DI scores are patient-reported outcome measures and rely on patient assessment about their disease, the presence of pain, tiredness and ability to perform daily activities, which can be influenced by variables not covered in the study, such as the presence of fibromyalgia, mood disorders and other comorbidities [29, 30]. Another limitation is missing data and inter-variability of questionnaire results applied for different physicians. The Rheumatology center minimizes this possible measurement bias by carrying out prior training of the researchers responsible for collecting data.

The strength of this study is that, to our knowledge, it is the first cohort of clinical assistance from the public health service of a developing country, contrasting with the controlled environment of randomized clinical trials. Also, we were able to achieve a longer follow-up time, with an average of 6 years, while most of previous studies evaluating function in PsA have follow-up times from 3 to 12 months [21,22,23].

Conclusion

In conclusion, we can postulate that, in the context of developing countries and limited resources, it is worth seeking to achieve lower disease activity scores by DAPSA, regardless of the treatment itself, because they are correlated to better functional outcomes. Higher HAQ-DI scores at baseline, non-white ethnicity and younger age were predictors for achieving a clinically significant improvement in HAQ-DI, reinforcing the importance of early treatment of PsA, before the establishment of deformities.

Availability of data and materials

Data and materials are available for review.

References

  1. Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48(1):28–34. https://doi.org/10.1016/j.semarthrit.2018.01.003. (Epub 2018 Jan 6).

    Article  PubMed  Google Scholar 

  2. Mease P, Strand V. Functional impairment measurement in psoriatic arthritis: importance and challenges. Semin Arthritis Rheum. 2018;48(3):436–48.

    Article  PubMed  Google Scholar 

  3. Coates LC, Moverley AR, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. The Lancet. 2015;386:19–26.

    Article  Google Scholar 

  4. Aletaha D, Alasti F, Smolen JS. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. Ann Rheum Dis. 2017;76(2):418–21.

    Article  CAS  PubMed  Google Scholar 

  5. Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the Go-REVEAL study). Annal Rheum Dis. 2014;73:1689–94.

    Article  CAS  Google Scholar 

  6. Gossec L, Smolen JS, Ramiro S, et al. European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499–510.

    Article  CAS  PubMed  Google Scholar 

  7. Singh JA, Guyatt G, Ogdie A, et al. 2018 American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheum. 2019;71(1):5–32.

    Article  Google Scholar 

  8. Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060.

    Article  PubMed  Google Scholar 

  9. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811.

    Article  PubMed  Google Scholar 

  10. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res. 2010;62(7):965–9.

    Article  Google Scholar 

  11. The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36(6):729–40. https://doi.org/10.1002/art.1780360601.

  12. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137–45.

    Article  CAS  PubMed  Google Scholar 

  13. Husted JA, Gladman DD, Cook RJ, Farewell VJ. Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol. 1998;25:2146–55.

    CAS  PubMed  Google Scholar 

  14. Mease PJ. Measures of psoriatic arthritis: tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), mander/newcastle enthesitis index (MEI), leeds enthesitis index (LEI), spondyloarthritis research consortium of Canada (SPARCC), maastricht ankylosing spondylitis enthesis score (MASES), leeds dactylitis index (LDI), Patient global for psoriatic arthritis, dermatology life quality index (DLQI), psoriatic arthritis quality of life (PsAQOL), functional assessment of chronic illness therapy-fatigue (FACIT-F), psoriatic arthritis response criteria (PsARC), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), and composite psoriatic disease activity index (CPDAI). Arthritis Care Res. 2011;63(Suppl 11):S64–85.

    Google Scholar 

  15. Strand V, Alemao E. Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from phase 3 trial. Arthritis Res Ther. 2018;20(1):269.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Gottlieb AB, Langley RG. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials. J Drugs Dermatol. 2015;14(8):821–3.

    PubMed  Google Scholar 

  17. Rahman P, Zummer M, Bessette L, Baer P, Haraoui B, Chow A, Kelsall J, Kapur S, Rampakakis E, Psaradellis E, Lehman AJ. Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry. BMJ Open. 2017;7(8):e016619.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthr Rheum Off J Am College Rheumatol. 2006;54(8):2665–73.

    Article  Google Scholar 

  19. Haddad A, Thavaneswaran A, Ruiz-Arruza I, et al. Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res. 2015;67:842–7.

    Article  CAS  Google Scholar 

  20. Leung YY, Ho KW, Li E, et al. Predictors of functional deterioration in Chinese patients with psoriatic arthritis: a longitudinal study. BMC Musculoskelet Disord. 2014;15:284.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Strand V, Mease P, Gossec L, et al. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann Rheum Dis. 2017;76:48–55.

    Article  Google Scholar 

  22. Kavanaugh A, Kruegger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007;66:498–505.

    Article  CAS  PubMed  Google Scholar 

  23. Wervers K, Vis M, Tchetverikov I, Gerards AH, Kok MR, Appels CW, van der Graaff WL, van Groenendael JH, Korswagen LA, Veris-Van Dieren JJ, Hazes JM. THU0289 Burden of psoriatic arthritis in different definitions of disease activity: comparing minimal disease activity and disease activity index for psoriatic arthritis. Annal Rheum Dis. 2018;1(77):363.

    Google Scholar 

  24. Gratacós J, Daudén E, Reino JG, et al. Health-related quality of life in psoriatic arthritis patients in Spain. Reumatología Clínica. 2014;10(1):25–31.

    Article  PubMed  Google Scholar 

  25. Husted JA, Tom BD, Farewell VT, et al. Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. Arthr Rheumatol. 2005;53:404–9.

    Article  Google Scholar 

  26. Migkos MP, Somarakis GP, Markatseli TE, Voulgari PV, Drosos AA. Epidemiological characteristics of psoriatic arthritis. Clin Exp Rheumatol. 2019;37(2):324–32.

    PubMed  Google Scholar 

  27. Kerr GS, Qaiyumi S, Richards J, et al. Psoriasis and psoriatic arthritis in African–American patients - the need to measure disease burden. Clin Rheumatol. 2015;34:1753–9.

    Article  PubMed  Google Scholar 

  28. Rahman P, Puig L, Gottlieb AB, et al. Ustekinumab treatment and improvement of physical function and health-related quality of life in patients with psoriatic arthritis. Arthritis Care Res. 2016;68:1812–22.

    Article  CAS  Google Scholar 

  29. Ulus Y, Akyol Y, et al. The impact of the presence of fibromyalgia on fatigue in patients with psoriatic arthritis: comparison with controls. Adv Rheumatol. 2019;60(1):1.

    Article  PubMed  Google Scholar 

  30. Zhao SS, Duffield SJ, et al. The prevalence and impact of comorbid fibromyalgia in inflammatory arthritis. Best Pract Res Clin Rheumatol. 2019;33(3):101423.

    Article  PubMed  Google Scholar 

  31. Coates LC et al. GRAPPA treatment recommendations: 2021 update. J Rheumatol 2022;49(6 Suppl 1):52–54. https://doi.org/10.3899/jrheum.211331

    Article  Google Scholar 

  32. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700–12.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Novartis collaborated with the study.

Author information

Author notes

  1. Larissa Vargas Cruz and Júlia Boechat Farani contributted equally to this study.

Authors and Affiliations

  1. Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil

    Larissa Vargas Cruz, Júlia Boechat Farani, Franciele de Almeida Menegat, Andrese Aline Gasparin, Claiton Viegas Brenol, Charles Lubianca Kohem & Penélope Esther Palominos

  2. Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil

    Júlia Rabello Costa, João Victor de Andrade Águas, Bruna Ruschel, Claiton Viegas Brenol & Charles Lubianca Kohem

  3. Novartis Biociências, Porto Alegre, Brazil

    Adrieli Bessa, Francisco Forestiero & Felipe Thies

Authors
  1. Larissa Vargas Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Júlia Boechat Farani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Júlia Rabello Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. João Victor de Andrade Águas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bruna Ruschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Franciele de Almeida Menegat
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrese Aline Gasparin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Claiton Viegas Brenol
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Charles Lubianca Kohem
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Adrieli Bessa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Francisco Forestiero
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Felipe Thies
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Penélope Esther Palominos
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors participated in data collection, data analysis and writing.

Corresponding author

Correspondence to Larissa Vargas Cruz.

Ethics declarations

Ethical approval and consent to participate

The study was approved by the Hospital de Clínicas de Porto Alegre's ethics comittee. The written informed consent from patients was not required because it was a retrospective study with data from routine care.

Consent for publication

All authors agree with the publication of the study in the journal Advances in Rheumatology.

Competing interests

Novartis collaborated with the study, but did not participate in the data collection, analysis or description of the results.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cruz, L.V., Farani, J.B., Costa, J.R. et al. Patients with longstanding psoriatic arthritis can achieve DAPSA remission or low disease activity and it correlates to better functional outcomes: results from a Latin-American real-life cohort. Adv Rheumatol 64, 3 (2024). https://doi.org/10.1186/s42358-023-00338-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s42358-023-00338-8

Keywords

Advances in Rheumatology

ISSN: 2523-3106